302 related articles for article (PubMed ID: 36746512)
1. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
2. Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Wang Y; Chen D; Pan Y; Li H; Zhao W; Lu T; Kong W; Ding M; Wang X; Zhang G
Rev Med Virol; 2024 Jan; 34(1):e2495. PubMed ID: 38017632
[TBL] [Abstract][Full Text] [Related]
3. Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade.
Widman AJ; Cohen B; Park V; McClure T; Wolchok J; Kamboj M
J Natl Compr Canc Netw; 2022 Oct; 20(10):1134-1138. PubMed ID: 36240845
[TBL] [Abstract][Full Text] [Related]
4. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
6. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
8. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis.
Becerril-Gaitan A; Vaca-Cartagena BF; Ferrigno AS; Mesa-Chavez F; Barrientos-Gutiérrez T; Tagliamento M; Lambertini M; Villarreal-Garza C
Eur J Cancer; 2022 Jan; 160():243-260. PubMed ID: 34794855
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A; Dettorre GM; Dafni U; Aguilar-Company J; Castelo-Branco L; Lambertini M; Gennatas S; Angelis V; Sita-Lumsden A; Rogado J; Pedrazzoli P; Viñal D; Prat A; Rossi M; Berardi R; Alonso-Gordoa T; Grisanti S; Dimopoulou G; Queirolo P; Pradervand S; Bertuzzi A; Bower M; Arnold D; Salazar R; Tucci M; Harrington KJ; Mazzoni F; Mukherjee U; Tsourti Z; Michielin O; Pommeret F; Brunet J; Vincenzi B; Tonini G; Patriarca A; Biello F; Krengli M; Tabernero J; Pentheroudakis G; Gennari A; Peters S; Romano E; Pinato DJ
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450384
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis.
Ma Y; Liu N; Wang Y; Zeng J; Hu YY; Hao W; Shi H; Zhu P; Lv J; Fan W; Wang X
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34845005
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 Outcomes in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Precis Oncol; 2023 May; 6(2):103-110. PubMed ID: 37214207
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
17. Influenza Vaccination in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Tsiakos K; Kyriakoulis KG; Kollias A; Kyriakoulis IG; Poulakou G; Syrigos K
J Immunother; 2022 Jul-Aug 01; 45(6):291-298. PubMed ID: 35639000
[TBL] [Abstract][Full Text] [Related]
18. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis.
Watanabe A; Kani R; Iwagami M; Takagi H; Yasuhara J; Kuno T
JAMA Pediatr; 2023 Apr; 177(4):384-394. PubMed ID: 36689319
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
